Gapping Up:
In reaction to earnings/guidance:
- CR +8.2%, RMBS +6.8%, SWFT +5.8%, ORAN +5.1%, BHI +4.5%, CLGX+4.3%, RDY +3.7%, KKR +3.6%, BAX +3.2%, KEY +3.1%, VLO +2.9%, UTX+2.7%, ALSN +2.5%, PG +2.3%, UA +2.0%, MRK +1.6%, LMT +1.4%, GM+1.3%
Select metal/mining names seeing strength amid gains in underlying metals prices:
- HMY +3.3%, CLF +3.2%, MUX +3.1%, GFI +2.7%, VALE +2.6%, RIO +2.4%,BHP +1.6%, GOLD +1.3%, ABX +1.3%, GDX +1.0%, AU +1.0%.
Other news:
- SAEX +50.3% (received approx $24.4 mln of tax credit certificates from the state of Alaska's Department of Revenue; says received sooner than expected),
- GBT +18.3% (agrees w/ the FDA on the design of its pivotal trial for GBT440 in adults and adolescents with sickle cell disease; expected to begin screening patients by December; decides to discontinue its research and development activities related to GBT18713; Chief Medical Officer Dr. Eleanor Ramos retires),
- EYES +16.2% (announces the first successful implantation and activation of a wireless visual cortical stimulator in a human subject),
- PSTI +11.2% (to sell approx. 16.89 mln shares of common stock at $1.77/share to China-based Innovative Medical Management),
- CWEI +8.0% (Clayton Williams announces agreement to sell Giddings area assets for $400 million; names Patrick Cooke as COO),
- CANF +7.4% (announces agreement with Chong Kun Dang Pharma for the exclusive right to distribute CF102 for the treatment of liver cancer in South Korea for up to $3 mln in upfront/milestone payments, plus a % of royalties on net sales in the low twenties),
- WINT +7.4% (releases data from lung deposition study in non-human primates demonstrating uniform distribution of aerosolized KL4 surfactant in all regions of the lung),
- SYT +1.4% (modest relief following yesterday's weakness)
- BMY +1.3% (announces results from CheckMate-205; primary endpoint of objective response rate was 73% overall, which was consistent across patient subgroups)